268 related articles for article (PubMed ID: 25886299)
1. Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome.
Gambaro K; Quinn MC; Cáceres-Gorriti KY; Shapiro RS; Provencher D; Rahimi K; Mes-Masson AM; Tonin PN
BMC Cancer; 2015 Mar; 15():135. PubMed ID: 25886299
[TBL] [Abstract][Full Text] [Related]
2. FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome.
Quinn MC; Wojnarowicz PM; Pickett A; Provencher DM; Mes-Masson AM; Davis EC; Tonin PN
Int J Oncol; 2013 Mar; 42(3):912-20. PubMed ID: 23354471
[TBL] [Abstract][Full Text] [Related]
3. Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer.
Dahl ES; Buj R; Leon KE; Newell JM; Imamura Y; Bitler BG; Snyder NW; Aird KM
Mol Cancer Res; 2019 Aug; 17(8):1710-1720. PubMed ID: 31110157
[TBL] [Abstract][Full Text] [Related]
4. TRAIL-R3-related apoptosis: epigenetic and expression analyses in women with ovarian neoplasia.
Braga Lda C; Alvares da Silva Ramos AP; Traiman P; Silva LM; Lopes da Silva-Filho A
Gynecol Oncol; 2012 Aug; 126(2):268-73. PubMed ID: 22555108
[TBL] [Abstract][Full Text] [Related]
5. Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.
Bolomsky A; Hose D; Schreder M; Seckinger A; Lipp S; Klein B; Heintel D; Ludwig H; Zojer N
J Hematol Oncol; 2015 Feb; 8():10. PubMed ID: 25887188
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer.
Wojnarowicz PM; Provencher DM; Mes-Masson AM; Tonin PN
Int J Oncol; 2012 Jun; 40(6):1865-80. PubMed ID: 22344671
[TBL] [Abstract][Full Text] [Related]
7. The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells.
Faddaoui A; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Macdonald E; Vanderhyden B; Bachvarov D
Oncotarget; 2016 Mar; 7(12):14125-42. PubMed ID: 26871602
[TBL] [Abstract][Full Text] [Related]
8. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.
Zhang X; Guo G; Wang G; Zhao J; Wang B; Yu X; Ding Y
Mol Med Rep; 2015 Dec; 12(6):8021-31. PubMed ID: 26497752
[TBL] [Abstract][Full Text] [Related]
9. Long Non-Coding RNA HAND2-AS1 Acts as a Tumor Suppressor in High-Grade Serous Ovarian Carcinoma.
Gokulnath P; de Cristofaro T; Manipur I; Di Palma T; Soriano AA; Guarracino MR; Zannini M
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517089
[TBL] [Abstract][Full Text] [Related]
10. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
11.
Valle BL; Rodriguez-Torres S; Kuhn E; Díaz-Montes T; Parrilla-Castellar E; Lawson FP; Folawiyo O; Ili-Gangas C; Brebi-Mieville P; Eshleman JR; Herman J; Shih IM; Sidransky D; Guerrero-Preston R
Cancer Prev Res (Phila); 2020 Sep; 13(9):783-794. PubMed ID: 32581010
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
[TBL] [Abstract][Full Text] [Related]
13. [Expression of hSef and FGF-2 in epithelial ovarian tumor].
Feng QL; Shi HR; Qiao LJ; Zhao J
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):770-4. PubMed ID: 22335910
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
15. PRAME expression and promoter hypomethylation in epithelial ovarian cancer.
Zhang W; Barger CJ; Eng KH; Klinkebiel D; Link PA; Omilian A; Bshara W; Odunsi K; Karpf AR
Oncotarget; 2016 Jul; 7(29):45352-45369. PubMed ID: 27322684
[TBL] [Abstract][Full Text] [Related]
16. DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer.
Klinkebiel D; Zhang W; Akers SN; Odunsi K; Karpf AR
Mol Cancer Res; 2016 Sep; 14(9):787-94. PubMed ID: 27259716
[TBL] [Abstract][Full Text] [Related]
17. Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
Harrington BS; He Y; Davies CM; Wallace SJ; Adams MN; Beaven EA; Roche DK; Kennedy C; Chetty NP; Crandon AJ; Flatley C; Oliveira NB; Shannon CM; deFazio A; Tinker AV; Gilks CB; Gabrielli B; Brennan DJ; Coward JI; Armes JE; Perrin LC; Hooper JD
Br J Cancer; 2016 Feb; 114(4):417-26. PubMed ID: 26882065
[TBL] [Abstract][Full Text] [Related]
18. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
19. Upregulated CDK16 Expression in Serous Epithelial Ovarian Cancer Cells.
Zhou Q; Yu Y
Med Sci Monit; 2015 Nov; 21():3409-14. PubMed ID: 26546806
[TBL] [Abstract][Full Text] [Related]
20. IGFBP7 promoter methylation and gene expression analysis in prostate cancer.
Sullivan L; Murphy TM; Barrett C; Loftus B; Thornhill J; Lawler M; Hollywood D; Lynch T; Perry AS
J Urol; 2012 Oct; 188(4):1354-60. PubMed ID: 22906661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]